Free Trial

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Birchcliff Energy stock logo

1. Birchcliff Energy OTCMKTS:BIREF

$4.43 +0.01 (+0.33%)
As of 11:15 AM Eastern

Birchcliff Energy Ltd., an intermediate oil and natural gas company, explores for, develops, and produces natural gas, light oil, condensate, and other natural gas liquids in Western Canada. More about Birchcliff Energy

Market Capitalization
$1.21 billion
P/E Ratio
23.31
Consensus Rating
Strong Buy
Volume
3,717 shares
Average Volume
83,994 shares
Today's Range
$4.36
$4.45
Ultrapar Participacoes stock logo

2. Ultrapar Participacoes NYSE:UGP

$3.86 -0.04 (-0.90%)
As of 11:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ultrapar Participações SA, through its subsidiaries, operates in the energy and infrastructure business in Brazil. The company distributes liquefied petroleum gas to residential, commercial, and industrial consumers, in addition to renewable electricity and compressed natural gas. More about Ultrapar Participacoes

Market Capitalization
$4.31 billion
P/E Ratio
8.59
Consensus Rating
Buy
Consensus Price Target
$4.50 (+16.4% Upside)
Volume
383,578 shares
Average Volume
1.86 million shares
Perspective Therapeutics stock logo

3. Perspective Therapeutics NYSEAMERICAN:CATX

$3.16 -0.03 (-1.07%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization
$235.78 million
Consensus Rating
Buy
Consensus Price Target
$12.70 (+302.4% Upside)
Volume
1.38 million shares
Average Volume
970,075 shares
Today's Range
$2.90
$3.46
Western Copper & Gold stock logo

4. Western Copper & Gold NYSE:WRN

$2.13 -0.12 (-5.33%)
As of 11:11 AM Eastern

Western Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & Gold

Market Capitalization
$429.52 million
P/E Ratio
-106.50
Consensus Rating
Buy
Consensus Price Target
$4.25 (+99.5% Upside)
Volume
590,294 shares
Average Volume
495,495 shares
Scor stock logo

5. Scor OTCMKTS:SCRYY

$3.35 -0.18 (-5.03%)
As of 10/20/2025 03:53 PM Eastern

SCOR SE, together with its subsidiaries, provides life and non-life reinsurance products in Europe, the Middle East, Africa, the Americas, Latin America, and Asia Pacific. More about Scor

Market Capitalization
$6.02 billion
P/E Ratio
10.16
Consensus Rating
Buy
Volume
7,631 shares
Average Volume
31,230 shares
Today's Range
$3.34
$3.48
Foghorn Therapeutics stock logo

6. Foghorn Therapeutics NASDAQ:FHTX

$4.12 +0.08 (+1.86%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. More about Foghorn Therapeutics

Market Capitalization
$232.62 million
P/E Ratio
-3.46
Consensus Rating
Buy
Consensus Price Target
$11.00 (+167.3% Upside)
Volume
72,899 shares
Average Volume
131,257 shares
Vizsla Silver stock logo

7. Vizsla Silver NYSEAMERICAN:VZLA

$4.20 -0.50 (-10.55%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vizsla Silver Corp. engages in the exploration, and development of precious and base metal assets. The company explores for gold, silver, and copper deposits. More about Vizsla Silver

Market Capitalization
$1.43 billion
P/E Ratio
-104.65
Consensus Rating
Buy
Consensus Price Target
$3.25 (-22.5% Downside)
Volume
2.96 million shares
Average Volume
3.15 million shares
Gold Royalty stock logo

8. Gold Royalty NYSE:GROY

$3.56 -0.11 (-2.86%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. More about Gold Royalty

Market Capitalization
$611.14 million
P/E Ratio
-27.58
Consensus Rating
Buy
Consensus Price Target
$4.61 (+29.3% Upside)
Volume
2.64 million shares
Average Volume
1.91 million shares
Ur Energy stock logo

9. Ur Energy NYSEAMERICAN:URG

$1.52 -0.10 (-5.86%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$556.35 million
P/E Ratio
-8.91
Consensus Rating
Buy
Consensus Price Target
$2.44 (+60.0% Upside)
Volume
4.73 million shares
Average Volume
6.41 million shares
Nano-X Imaging stock logo

10. Nano-X Imaging NASDAQ:NNOX

$4.16 -0.06 (-1.30%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X Imaging

Market Capitalization
$241.81 million
P/E Ratio
-4.65
Consensus Rating
Buy
Consensus Price Target
$8.50 (+104.1% Upside)
Volume
334,830 shares
Average Volume
1.67 million shares
Denison Mine stock logo

11. Denison Mine NYSEAMERICAN:DNN

$2.72 -0.21 (-7.00%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison Mine

Market Capitalization
$2.43 billion
P/E Ratio
-45.25
Consensus Rating
Buy
Consensus Price Target
$2.75 (+0.9% Upside)
Volume
29.31 million shares
Average Volume
80.54 million shares
CuriosityStream stock logo

12. CuriosityStream NASDAQ:CURI

$4.58 -0.04 (-0.76%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CuriosityStream Inc operates as a factual content streaming service and media company. The company provides premium video and audio programming services in various categories of factual entertainment, including science, history, society, nature, lifestyle, and technology through direct subscription video on-demand (SVoD) platforms accessible by internet connected devices, or indirectly via distribution partners who deliver CuriosityStream content via distributor's platform or system, as well as through bundled content licenses for SVoD and linear offerings, talks and courses, and partner bulk sales. More about CuriosityStream

Market Capitalization
$264.74 million
P/E Ratio
-50.77
Consensus Rating
Buy
Consensus Price Target
$6.33 (+38.4% Upside)
Volume
55,159 shares
Average Volume
580,443 shares
TuHURA Biosciences stock logo

13. TuHURA Biosciences NASDAQ:HURA

$2.37 -0.08 (-3.27%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. More about TuHURA Biosciences

Market Capitalization
$121.11 million
Consensus Rating
Buy
Consensus Price Target
$12.67 (+434.5% Upside)
Volume
46,376 shares
Average Volume
287,728 shares
Today's Range
$2.31
$2.43
Climb Bio stock logo

14. Climb Bio NASDAQ:CLYM

$2.46 +0.14 (+6.03%)
As of 11:16 AM Eastern

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. More about Climb Bio

Market Capitalization
$166.69 million
P/E Ratio
-3.51
Consensus Rating
Buy
Consensus Price Target
$9.20 (+274.0% Upside)
Volume
575,015 shares
Average Volume
419,861 shares
Innventure stock logo

15. Innventure NASDAQ:INV

$3.05 -0.01 (-0.33%)
As of 11:06 AM Eastern

Innventure Inc founds, funds and operates companies with a focus on transformative, sustainable technology solutions acquired or licensed from multinational corporations. More about Innventure

Market Capitalization
$170.89 million
Consensus Rating
Buy
Consensus Price Target
$14.00 (+359.0% Upside)
Volume
100,199 shares
Average Volume
162,342 shares
Today's Range
$3.00
$3.22
Plus Therapeutics stock logo

16. Plus Therapeutics NASDAQ:PSTV

$0.64 +0.06 (+10.82%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus Therapeutics

Market Capitalization
$63.73 million
P/E Ratio
-0.29
Consensus Rating
Buy
Consensus Price Target
$8.00 (+1,146.1% Upside)
Volume
17.34 million shares
Average Volume
20.68 million shares
Marker Therapeutics stock logo

17. Marker Therapeutics NASDAQ:MRKR

$1.04 +0.01 (+0.87%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More about Marker Therapeutics

Market Capitalization
$13.46 million
P/E Ratio
-0.76
Consensus Rating
Buy
Consensus Price Target
$10.25 (+886.5% Upside)
Volume
44,360 shares
Average Volume
731,885 shares
Cardiol Therapeutics stock logo

18. Cardiol Therapeutics NASDAQ:CRDL

$1.14 +0.09 (+8.10%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol Therapeutics

Market Capitalization
$97.51 million
P/E Ratio
-3.28
Consensus Rating
Buy
Consensus Price Target
$8.00 (+604.8% Upside)
Volume
358,418 shares
Average Volume
451,980 shares
Talphera stock logo

19. Talphera NASDAQ:TLPH

$1.14 -0.01 (-0.87%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More about Talphera

Market Capitalization
$51.97 million
P/E Ratio
-2.85
Consensus Rating
Buy
Consensus Price Target
$5.00 (+338.6% Upside)
Volume
204,271 shares
Average Volume
911,976 shares
Quince Therapeutics stock logo

20. Quince Therapeutics NASDAQ:QNCX

$1.84 -0.02 (-0.81%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince Therapeutics

Market Capitalization
$98.62 million
P/E Ratio
-1.68
Consensus Rating
Buy
Consensus Price Target
$8.14 (+343.8% Upside)
Volume
74,708 shares
Average Volume
247,244 shares
Compass Therapeutics stock logo

21. Compass Therapeutics NASDAQ:CMPX

$4.24 +0.19 (+4.74%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass Therapeutics

Market Capitalization
$574.57 million
P/E Ratio
-9.23
Consensus Rating
Moderate Buy
Consensus Price Target
$13.10 (+208.8% Upside)
Volume
407,643 shares
Average Volume
1.42 million shares
Rezolve AI stock logo

22. Rezolve AI NASDAQ:RZLV

$4.86 -0.06 (-1.12%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. More about Rezolve AI

Market Capitalization
$1.01 billion
Consensus Rating
Moderate Buy
Consensus Price Target
$9.00 (+85.4% Upside)
Volume
4.17 million shares
Average Volume
10.63 million shares
Today's Range
$4.65
$4.87
Aclaris Therapeutics stock logo

23. Aclaris Therapeutics NASDAQ:ACRS

$2.35 +0.34 (+16.87%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris Therapeutics

Market Capitalization
$260.53 million
P/E Ratio
-1.76
Consensus Rating
Moderate Buy
Consensus Price Target
$8.71 (+271.0% Upside)
Volume
1.96 million shares
Average Volume
979,208 shares
Alumis stock logo

24. Alumis NASDAQ:ALMS

$4.78 +0.02 (+0.32%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. More about Alumis

Market Capitalization
$502.09 million
Consensus Rating
Moderate Buy
Consensus Price Target
$20.17 (+322.3% Upside)
Volume
73,285 shares
Average Volume
685,414 shares
Today's Range
$4.64
$4.81
Context Therapeutics stock logo

25. Context Therapeutics NASDAQ:CNTX

$1.30 -0.08 (-5.47%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$116.17 million
P/E Ratio
-3.60
Consensus Rating
Moderate Buy
Consensus Price Target
$5.20 (+301.5% Upside)
Volume
155,839 shares
Average Volume
225,067 shares